- Third-quarter sales growth of 2% on a reported basis, 5% organic
- Third-quarter Reconstructive sales growth of 6% on a reported and organic basis
- Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS
- Board of Directors approves new
$200 million share repurchase authorization
Third Quarter 2026 Financial Results
Enovis’ third-quarter net sales of
The Company reported third-quarter 2026 net income of
“Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline,” said
The environment remains dynamic, including volatility and cost inflation in many markets. Despite these challenges, we are investing in the technologies that will define the next phase of our growth, including our agreement to acquire eCential Robotics, while maintaining strong cost and capital discipline. Our focus remains on continuously improving how we operate and execute to make our performance repeatable, and increasingly profitable.”
2026 Financial Outlook
Share Repurchase Authorization
Conference call and Webcast
Investors can access the webcast via a link on the
About
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world.
Availability of Information on the Enovis Website
Investors and others should note that
Forward-Looking Statements
This press release includes forward-looking statements, including forward-looking statements within the meaning of the
Non-GAAP Financial Measures
Adjusted net income and Adjusted net income per diluted share exclude net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of income (loss) from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and property plant and equipment step-up depreciation; goodwill impairment charges; non-cash Other (income) expense, net; and include the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments.
Adjusted EBITDA represents Adjusted net income excluding all Other (income) expense, net; interest, taxes, and depreciation and other amortization.
Adjusted gross profit represents gross profit excluding depreciation step-up of acquired fixed assets and the impact of restructuring charges. Adjusted gross profit margin is subject to the same adjustments as Adjusted gross profit.
Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures, and foreign exchange rate fluctuations.
Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment net of proceeds from sale of certain properties. Free cash flow conversion represents free cash flow divided by adjusted net income.
These non-GAAP financial measures assist
Vice President, Investor Relations
investorrelations@enovis.com
Condensed Consolidated Statements of Operations
Dollars in thousands, except per share data
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| Net sales | $ | 558,725 | $ | 548,912 | $ | 1,730,658 | $ | 1,672,291 | ||||||||
| Cost of sales | 218,878 | 219,999 | 666,077 | 676,452 | ||||||||||||
| Gross profit | 339,847 | 328,913 | 1,064,581 | 995,839 | ||||||||||||
| Gross profit margin | 60.8 | % | 59.9 | % | 61.5 | % | 59.5 | % | ||||||||
| Selling, general and administrative expense | 259,375 | 263,621 | 805,915 | 799,714 | ||||||||||||
| Research and development expense | 31,275 | 29,739 | 94,494 | 88,967 | ||||||||||||
| Amortization of acquired intangibles | 43,254 | 43,689 | 126,719 | 128,463 | ||||||||||||
| Purchase of royalty interest | — | — | — | 45,818 | ||||||||||||
| Restructuring charges | 2,568 | 1,910 | 10,135 | 6,488 | ||||||||||||
| — | 548,442 | — | 548,442 | |||||||||||||
| Operating income (loss) | 3,375 | (558,488 | ) | 27,318 | (622,053 | ) | ||||||||||
| Operating income (loss) margin | 0.6 | % | (101.7) % | 1.6 | % | (37.2) % | ||||||||||
| Interest expense, net | 7,616 | 8,828 | 24,823 | 27,310 | ||||||||||||
| Other (income) expense, net | (3,785 | ) | (448 | ) | (5,148 | ) | 508 | |||||||||
| Income (loss) from continuing operations before income taxes | (456 | ) | (566,868 | ) | 7,643 | (649,871 | ) | |||||||||
| Income tax expense (benefit) | (1,679 | ) | 4,005 | 15,867 | 13,037 | |||||||||||
| Net income (loss) from continuing operations | 1,223 | (570,873 | ) | (8,224 | ) | (662,908 | ) | |||||||||
| Income (loss) from discontinued operations, net of taxes | 2,194 | (40 | ) | 2,155 | (258 | ) | ||||||||||
| Net income (loss) | 3,417 | (570,913 | ) | (6,069 | ) | (663,166 | ) | |||||||||
| Net income (loss) margin | 0.6 | % | (104.0) % | (0.4) % | (39.7) % | |||||||||||
| Less: net income attributable to noncontrolling interest from continuing operations - net of taxes | 278 | 233 | 746 | 685 | ||||||||||||
| Net income (loss) attributable to | $ | 3,139 | $ | (571,146 | ) | $ | (6,815 | ) | $ | (663,851 | ) | |||||
| Net income (loss) per share - basic and diluted | ||||||||||||||||
| Continuing operations | $ | 0.02 | $ | (9.99 | ) | $ | (0.16 | ) | $ | (11.64 | ) | |||||
| Discontinued operations | $ | 0.04 | $ | — | $ | 0.04 | $ | — | ||||||||
| Consolidated operations | $ | 0.06 | $ | (9.99 | ) | $ | (0.12 | ) | $ | (11.64 | ) | |||||
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Adjusted Net Income and Adjusted Net Income Per Share | |||||||||||||||
| Net income (loss) (GAAP) | $ | 3.4 | $ | (570.9 | ) | $ | (6.1 | ) | $ | (663.2 | ) | ||||
| Net income (loss) margin (GAAP) | 0.6 | % | (104.0) % | (0.4) % | (39.7) % | ||||||||||
| Net loss attributable to noncontrolling interest from continuing operations - net of taxes | (0.3 | ) | (0.2 | ) | (0.7 | ) | (0.7 | ) | |||||||
| Loss (Income) from discontinued operations, net of taxes | (2.2 | ) | — | (2.2 | ) | 0.3 | |||||||||
| Net income (loss) from continuing operations attributable to | $ | 0.9 | $ | (571.1 | ) | $ | (9.0 | ) | $ | (663.6 | ) | ||||
| Restructuring charges - pretax(2) | 2.6 | 3.4 | 10.1 | 8.2 | |||||||||||
| MDR and other costs - pretax(3) | 0.9 | 2.4 | 2.8 | 9.0 | |||||||||||
| Amortization of acquired intangibles - pretax | 43.3 | 43.7 | 126.7 | 128.5 | |||||||||||
| — | 548.4 | — | 548.4 | ||||||||||||
| PPE step-up depreciation - pretax(4) | 0.6 | 0.7 | 1.9 | 1.9 | |||||||||||
| Strategic transaction costs - pretax(5) | 15.6 | 15.7 | 28.1 | 41.2 | |||||||||||
| Purchase of royalty interest(6) | — | — | — | 45.8 | |||||||||||
| Stock-based compensation | 7.5 | 9.0 | 25.2 | 25.0 | |||||||||||
| Other (income) expense, net(7) | (2.9 | ) | (0.4 | ) | (0.6 | ) | 0.5 | ||||||||
| Tax adjustment(8) | (17.1 | ) | (8.2 | ) | (30.0 | ) | (22.9 | ) | |||||||
| Adjusted net income from continuing operations (non-GAAP)(9) | $ | 51.4 | $ | 43.5 | $ | 155.2 | $ | 122.1 | |||||||
| Adjusted net income margin from continuing operations(9) | 9.2 | % | 7.9 | % | 9.0 | % | 7.3 | % | |||||||
| Weighted-average shares outstanding - diluted (GAAP) | 57,672 | 57,169 | 57,527 | 57,029 | |||||||||||
| Net loss per share - diluted from continuing operations (GAAP) | $ | 0.02 | $ | (9.99 | ) | $ | (0.16 | ) | $ | (11.64 | ) | ||||
| Adjusted weighted-average shares outstanding - diluted (non-GAAP) | 58,493 | 57,725 | 58,241 | 57,558 | |||||||||||
| Adjusted net income per share - diluted from continuing operations (non-GAAP)(9) | $ | 0.88 | $ | 0.75 | $ | 2.67 | $ | 2.12 | |||||||
__________
(1) Net income (loss) from continuing operations attributable to
(2) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability” included in our Form 10-Q. Includes expenses of
(3) MDR and other costs includes (i)
(4) Includes
(5) Strategic transaction costs includes: (i)
(6) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.
(7) Other (income) expense, net includes the fair value gain adjustment for non-designated cross currency swaps in 2026. Includes the final fair value loss adjustment for the Contingent Acquisition Shares issued in the first quarter of 2025.
(8) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 23.0% and 22.7% for the three and nine months ended
(9) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted Net Income and Adjusted Net Income Per Diluted Share to no longer adjust for inventory step-up charges. Adjusted Net Income in prior periods has been revised to reflect this change for consistency of presentation along with its impact on the effective tax rate which has been revised from 22.9%, as presented in our Form 8-K for the nine months ended
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| (Dollars in millions) | |||||||||||||||
| Net income (loss) (GAAP) | $ | 3.4 | $ | (570.9 | ) | $ | (6.1 | ) | $ | (663.2 | ) | ||||
| Net income (loss) margin (GAAP) | 0.6 | % | (104.0) % | (0.4) % | (39.7) % | ||||||||||
| Loss (Income) from discontinued operations, net of taxes | (2.2 | ) | — | (2.2 | ) | 0.3 | |||||||||
| Income tax expense (benefit) | (1.7 | ) | 4.0 | 15.9 | 13.0 | ||||||||||
| Other (income) expense, net | (3.8 | ) | (0.4 | ) | (5.1 | ) | 0.5 | ||||||||
| Interest expense, net | 7.6 | 8.8 | 24.8 | 27.3 | |||||||||||
| Operating income (loss) (GAAP) | $ | 3.4 | $ | (558.5 | ) | $ | 27.3 | $ | (622.1 | ) | |||||
| Adjusted to add: | |||||||||||||||
| Restructuring charges(1) | 2.6 | 3.4 | 10.1 | 8.2 | |||||||||||
| MDR and other costs(2) | 0.9 | 2.4 | 2.8 | 9.0 | |||||||||||
| Strategic transaction costs(3) | 15.6 | 15.7 | 28.1 | 41.2 | |||||||||||
| Stock-based compensation | 7.5 | 9.0 | 25.2 | 25.0 | |||||||||||
| Depreciation and other amortization | 30.2 | 30.7 | 91.2 | 88.9 | |||||||||||
| Amortization of acquired intangibles | 43.3 | 43.7 | 126.7 | 128.5 | |||||||||||
| — | 548.4 | — | 548.4 | ||||||||||||
| Purchase of royalty interest(4) | — | — | — | 45.8 | |||||||||||
| Adjusted EBITDA (non-GAAP)(5) | $ | 103.5 | $ | 94.8 | $ | 311.4 | $ | 273.0 | |||||||
| Adjusted EBITDA margin (non-GAAP)(5) | 18.5 | % | 17.3 | % | 18.0 | % | 16.3 | % | |||||||
__________
(1) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability” included in our Form 10-Q. Includes expenses of
(2) MDR and other costs includes (i)
(3) Strategic transaction costs includes: (i)
(4) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.
(5) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the nine months ended
Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)
Dollars in millions
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net sales | $ | 558.7 | $ | 548.9 | $ | 1,730.7 | $ | 1,672.3 | |||||||
| Gross profit | $ | 339.8 | $ | 328.9 | $ | 1,064.6 | $ | 995.8 | |||||||
| Gross profit margin (GAAP) | 60.8 | % | 59.9 | % | 61.5 | % | 59.5 | % | |||||||
| Gross profit (GAAP) | $ | 339.8 | $ | 328.9 | $ | 1,064.6 | $ | 995.8 | |||||||
| PPE step-up depreciation | 0.6 | 0.6 | 1.7 | 1.6 | |||||||||||
| Restructuring charges | — | 1.5 | — | 1.7 | |||||||||||
| Adjusted gross profit (Non-GAAP)(1) | $ | 340.4 | $ | 331.0 | $ | 1,066.3 | $ | 999.2 | |||||||
| Adjusted gross profit margin (Non-GAAP)(1) | 60.9 | % | 60.3 | % | 61.6 | % | 59.8 | % | |||||||
__________
(1) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted gross profit to no longer adjust for inventory step-up charges. Adjusted gross profit in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted gross profit for the nine months ended
Condensed Consolidated Balance Sheets
Dollars in thousands, except share amounts
(Unaudited)
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ | 13,038 | $ | 36,389 | |||
| Trade receivables, less allowance for credit losses of | 428,288 | 442,786 | |||||
| Inventories, net | 620,155 | 584,379 | |||||
| Prepaid expenses | 48,602 | 42,283 | |||||
| Other current assets | 137,493 | 101,222 | |||||
| Total current assets | 1,247,576 | 1,207,059 | |||||
| Property, plant and equipment, net | 526,315 | 507,063 | |||||
| 702,090 | 718,299 | ||||||
| Intangible assets, net | 1,093,942 | 1,236,713 | |||||
| Lease asset - right of use | 74,714 | 72,256 | |||||
| Other assets | 90,907 | 93,347 | |||||
| Total assets | $ | 3,735,544 | $ | 3,834,737 | |||
| LIABILITIES AND EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Current portion of long-term debt | $ | 35,000 | $ | 35,000 | |||
| Accounts payable | 200,449 | 187,531 | |||||
| Accrued liabilities | 344,389 | 375,943 | |||||
| Total current liabilities | 579,838 | 598,474 | |||||
| Long-term debt, less current portion | 1,223,261 | 1,261,793 | |||||
| Non-current lease liability | 59,985 | 58,000 | |||||
| Other liabilities | 376,877 | 424,568 | |||||
| Total liabilities | 2,239,961 | 2,342,835 | |||||
| Equity: | |||||||
| Common stock, | 58 | 57 | |||||
| Additional paid-in capital | 3,073,646 | 3,048,414 | |||||
| Accumulated deficit | (1,474,278 | ) | (1,467,463 | ) | |||
| Accumulated other comprehensive loss | (106,185 | ) | (91,363 | ) | |||
| Total | 1,493,241 | 1,489,645 | |||||
| Noncontrolling interest | 2,342 | 2,257 | |||||
| Total equity | 1,495,583 | 1,491,902 | |||||
| Total liabilities and equity | $ | 3,735,544 | $ | 3,834,737 | |||
Condensed Consolidated Statements of Cash Flows
Dollars in thousands
(Unaudited)
| Nine Months Ended | |||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (6,069 | ) | $ | (663,166 | ) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 217,884 | 217,366 | |||||
| Impairment of goodwill | — | 548,442 | |||||
| Stock-based compensation expense | 25,470 | 24,809 | |||||
| Non-cash interest expense | 5,929 | 5,120 | |||||
| Fair value loss on contingent acquisition shares | — | 1,787 | |||||
| Deferred income tax benefit | (42,241 | ) | (565 | ) | |||
| Loss on disposal of property, plant and equipment | 960 | 1,129 | |||||
| Changes in operating assets and liabilities: | |||||||
| Trade receivables, net | 7,588 | (17 | ) | ||||
| Inventories, net | (44,283 | ) | (33,153 | ) | |||
| Accounts payable | 15,602 | 10,345 | |||||
| Other operating assets and liabilities | (10,364 | ) | 16,652 | ||||
| Net cash provided by operating activities | 170,476 | 128,749 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property, plant and equipment and intangibles | (133,204 | ) | (141,122 | ) | |||
| Payments for acquisitions, net of cash received, and investments | (4,122 | ) | (26,859 | ) | |||
| Cash received (paid) for net investment hedge derivatives | (3,283 | ) | 1,601 | ||||
| Net cash used in investing activities | (140,609 | ) | (166,380 | ) | |||
| Cash flows from financing activities: | |||||||
| Repayments of borrowings under term credit facility | (26,250 | ) | (15,000 | ) | |||
| Proceeds from borrowings on revolving credit facilities and other | 172,000 | 177,000 | |||||
| Repayments of borrowings on revolving credit facilities and other | (189,041 | ) | (136,862 | ) | |||
| Payments of tax withholding for stock-based awards | (1,473 | ) | (3,504 | ) | |||
| Proceeds from issuance of common stock, net | 1,354 | 1,318 | |||||
| Deferred consideration payments and other | (9,637 | ) | (2,437 | ) | |||
| Net cash provided by (used in) financing activities | (53,047 | ) | 20,515 | ||||
| Effect of foreign exchange rates on Cash and cash equivalents | (171 | ) | 2,566 | ||||
| Decrease in Cash and cash equivalents | (23,351 | ) | (14,550 | ) | |||
| Cash and cash equivalents, beginning of period | 36,389 | 48,167 | |||||
| Cash and cash equivalents, end of period | $ | 13,038 | $ | 33,617 | |||
GAAP
Dollars in millions
(Unaudited)
| Three Months Ended | ||||||||||||||
| Growth Rate | Constant Currency Growth Rate (1) | Organic Growth Rate (2) | ||||||||||||
| (In millions) | ||||||||||||||
| Prevention & Recovery: | ||||||||||||||
| $ | 132.7 | $ | 127.0 | 4.5 | % | 4.5 | % | 4.5 | % | |||||
| 61.3 | 71.4 | (14.2) | % | (14.2) | % | 5.1 | % | |||||||
| International P&R | 91.4 | 92.6 | (1.2) | % | (0.7) | % | (0.7) | % | ||||||
| Total Prevention & Recovery | 285.4 | 290.9 | (1.9) | % | (1.7) | % | 3.0 | % | ||||||
| Reconstructive: | ||||||||||||||
| 135.3 | 129.0 | 4.9 | % | 4.9 | % | 4.9 | % | |||||||
| International Reconstructive | 138.0 | 129.0 | 7.0 | % | 7.8 | % | 7.8 | % | ||||||
| Total Reconstructive | 273.3 | 258.0 | 6.0 | % | 6.3 | % | 6.3 | % | ||||||
| Total | $ | 558.7 | $ | 548.9 | 1.8 | % | 2.1 | % | 4.6 | % | ||||
(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.
(3) The three months ended
GAAP
Dollars in millions
(Unaudited)
| Nine Months Ended | ||||||||||||||
| Growth Rate | Constant Currency Growth Rate (1) | Organic Growth Rate (2) | ||||||||||||
| (In millions) | ||||||||||||||
| Prevention & Recovery: | ||||||||||||||
| $ | 375.2 | $ | 362.9 | 3.4 | % | 3.4 | % | 3.4 | % | |||||
| 176.8 | 208.9 | (15.4) | % | (15.4) | % | 4.2 | % | |||||||
| International P&R | 293.7 | 282.3 | 4.0 | % | 0.5 | % | 0.1 | % | ||||||
| Total Prevention & Recovery | 845.7 | 854.1 | (1.0) | % | (2.1) | % | 2.5 | % | ||||||
| Reconstructive: | ||||||||||||||
| 422.4 | 396.3 | 6.6 | % | 6.6 | % | 6.6 | % | |||||||
| International Reconstructive | 462.6 | 421.8 | 9.7 | % | 5.5 | % | 5.5 | % | ||||||
| Total Reconstructive | 885.0 | 818.2 | 8.2 | % | 6.0 | % | 6.0 | % | ||||||
| Total | $ | 1,730.7 | $ | 1,672.3 | 3.5 | % | 1.9 | % | 4.2 | % | ||||
(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.
(3) The nine months ended
Change in
Dollars in millions
(Unaudited)
| Prevention and Recovery | Reconstructive | Total | ||||||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | |||||||||||||||
| For the three months ended | $ | 290.9 | $ | 258.0 | $ | 548.9 | ||||||||||||||
| Components of Change: | ||||||||||||||||||||
| Existing Businesses(1) | 8.7 | 3.0 | % | 16.3 | 6.3 | % | 25.0 | 4.6 | % | |||||||||||
| Acquisitions(2) | — | — | % | — | — | % | — | — | % | |||||||||||
| Divestitures(3) | (13.8 | ) | (4.7) | % | — | — | % | (13.8 | ) | (2.5) | % | |||||||||
| Foreign Currency Translation(4) | (0.4 | ) | (0.1) | % | (1.0 | ) | (0.4) | % | (1.4 | ) | (0.3) | % | ||||||||
| (5.5 | ) | (1.9) | % | 15.3 | 6.0 | % | 9.8 | 1.8 | % | |||||||||||
| For the three months ended | $ | 285.4 | $ | 273.3 | $ | 558.7 | ||||||||||||||
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
| Prevention and Recovery | Reconstructive | Total | |||||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | ||||||||||||||
| For the nine months ended | $ | 854.1 | $ | 818.2 | $ | 1,672.3 | |||||||||||||
| Components of Change: | |||||||||||||||||||
| Existing Businesses(1) | 21.3 | 2.5 | % | 49.3 | 6.0 | % | 70.6 | 4.2 | % | ||||||||||
| Acquisitions(2) | 1.3 | 0.2 | % | — | — | % | 1.3 | 0.1 | % | ||||||||||
| Divestitures(3) | (40.9 | ) | (4.8) | % | — | — | % | (40.9 | ) | (2.4) | % | ||||||||
| Foreign Currency Translation(4) | 9.9 | 1.2 | % | 17.5 | 2.1 | % | 27.4 | 1.6 | % | ||||||||||
| (8.4 | ) | (1.0) | % | 66.8 | 8.2 | % | 58.4 | 3.5 | % | ||||||||||
| For the nine months ended | $ | 845.7 | $ | 885.0 | $ | 1,730.7 | |||||||||||||
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
Source: